Skip to main content

Advertisement

SpringerLink
Log in

Sacubitril/Valsartan: From Clinical Trials to Real-world Experience

  • Heart Failure (W Tang, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Abstract

Purpose of review

Compared to enalapril, use of angiotensin-receptor blocker and neprilysin inhibitor sacubitril/valsartan to treat patients with heart failure and reduced ejection fraction (HFrEF) is associated with substantial reductions in both cardiovascular mortality and heart failure progression. The purpose of this review is to discuss the real-world experience of sacubitril/valsartan.

Recent findings

In the years following the publication of the landmark PARADIGM-HF trial in 2014 and its subsequent FDA approval, a growing evidence base supports the safety and efficacy of sacubitril/valsartan in a broad spectrum of patients with HFrEF. Updated clinical practice guidelines have embraced the use of sacubitril/valsartan in preference to ACE inhibitors or ARBs in selected patients.

Summary

In this review, we highlight the clinical trials that led to these key updates to clinical guidelines, offer practical strategies for patient selection and utilization in clinical practice, and identify important areas of uncertainty that require future research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Cardiac Failure. 2017;23:628–51. Highly referenced by clinicians managing patients with heart failure, this is the comprehensive yet concise update published by the ACC/AHA Task Force on Clinical Practice Guidelines as well as the HFSA, which advises substitution with ARNI in patients tolerating ACE inhibitor or ARB therapy. This update reflects the substantial reduction in cardiovascular mortality and heart failure hospitalizations related to ARNI therapy seen in PARADIGM-HF.

    Article  Google Scholar 

  2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.

    Article  PubMed  Google Scholar 

  3. Luo N, Fonarow GC, Lippmann SJ, Mi X, Heidenreich PA, Yancy CW, et al. Early adoption of sacubitril/valsartan for patients with heart failure with reduced ejection fraction: insights from get with the guidelines-heart failure (GWTG-HF). JACC Heart Fail. 2017;5(4):305–9.

    Article  PubMed  Google Scholar 

  4. Vardeny O, Tacheny T, Solomon SD. First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharmacol Ther. 2013;94(4):445–8.

    Article  PubMed  CAS  Google Scholar 

  5. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial. Am J Hypertens. 2004;17(2):103–11.

    Article  PubMed  CAS  Google Scholar 

  6. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE). Circulation. 2002;106(8):920–6.

    Article  PubMed  CAS  Google Scholar 

  7. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci. 2005;99(1):6–38.

    Article  PubMed  CAS  Google Scholar 

  8. Fryer RM, Segreti J, Banfor PN, Widomski DL, Backes BJ, Lin CW, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol. 2008;153(5):947–55.

    Article  PubMed  CAS  Google Scholar 

  9. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401–14.

    Article  PubMed  CAS  Google Scholar 

  10. •• McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. This is the landmark report on the PARADIGM-HF trial comparing angiotensin-neprilysin inhibition versus enalapril alone in symptomatic patients with reduced ejection fraction. In response to the 20% reduction in morbidity and mortality associated with heart failure in patients assigned to the study drug, the US Food and Drug Administration approved sacubitril/valsartan less than a year after the results of PARADIGM-HF were published.

    Article  PubMed  CAS  Google Scholar 

  11. Desai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36(30):1990–7.

    Article  PubMed  CAS  Google Scholar 

  12. Claggett B, Packer M, McMurray JJ, Swedberg K, Rouleau J, Zile MR, et al. Estimating the long-term treatment benefits of sacubitril-valsartan. N Engl J Med. 2015;373(23):2289–90.

    Article  PubMed  Google Scholar 

  13. Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36(38):2576–84.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, et al. Effects of sacubitril/valsartan in the PARADIGM-HF trial (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure) according to background therapy. Circ Heart Fail. 2016;9(9). https://doi.org/10.1161/CIRCHEARTFAILURE.116.003212.

  15. •• Simpson J, Jhund PS, Silva Cardoso J, Martinez F, Mosterd A, Ramires F, et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol. 2015;66(19):2059–71. This thoughtful analysis by Simpson et al. categorized the PARADIGM-HF patient population using two objective risk scoring systems, MAGGIC and EMPHASIS-HF, in order to examine the treatment effect of sacubitril/valsartan vs. enalapril across more granular risk score profiles. They found that the benefit of ARNI therapy over ACE inhibitor alone was in fact consistent across all levels of risk.

    Article  PubMed  CAS  Google Scholar 

  16. • Lewis EF, Claggett BL, McMurray JJV, Packer M, Lefkowitz MP, Rouleau JL, et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017;10(8). https://doi.org/10.1161/CIRCHEARTFAILURE.116.003430.This analysis of PARADIGM-HF provided evidence that the substantial reduction in cardiovascular morbidity and mortality associated with ARNI therapy also leads to improved markers of health-related quality of life.

  17. King JB, Shah RU, Bress AP, Nelson RE, Bellows BK. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2016;4(5):392–402.

    Article  PubMed  Google Scholar 

  18. Institute for Clinical and Economic Review. CardioMEMS™ HF system (St. Jude Medical) and sacubitril/valsartan (Entresto™, Novartis) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks. Available at: https://icer-review.org/wp-content/uploads/2016/01/CHF_Draft_Report_091115.pdf.

  19. Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, et al. Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol. 2016;1(6):666–72.

    Article  PubMed  Google Scholar 

  20. Desai AS, Solomon S, Claggett B, McMurray JJ, Rouleau J, Swedberg K, et al. Factors associated with noncompletion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF Trial. Circ Heart Fail. 2016 Jun;9(6). https://doi.org/10.1161/CIRCHEARTFAILURE.115.002735.

  21. Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017;38(15):1132–43.

    Article  PubMed  PubMed Central  Google Scholar 

  22. • Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of Sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2017;2(1):79–85. In this analysis, the incidence of hyperkalemia were compared between patients treated with sacubitril/valsartan vs. enalapril. Among patients taking a mineralocorticoid receptor antagonist (MRA) at baseline, overall rates of hyperkalemia were similar. Among those patients newly starting an MRA, severe hyperkalemia was more common in patients taking enalapril.

    Article  PubMed  Google Scholar 

  23. Damman K, Andersen K, Belohlavek J, Lefkowitz MP, Rouleau JL, Solomon SD, et al. Angiotensin receptor neprilysin inhibition and renal function and in heart failure: results from PARADIGM-HF. Eur Heart J. 2015;36(Abstract Supplement):545.

    Google Scholar 

  24. Feldman AM, Haller JA, DeKosky ST. Valsartan/sacubitril for heart failure: reconciling disparities between preclinical and clinical investigations. JAMA. 2016;315(1):25–6.

    Article  PubMed  CAS  Google Scholar 

  25. Vodovar N, Paquet C, Mebazaa A, Launay JM, Hugon J, Cohen-Solal A. Neprilysin, cardiovascular, and Alzheimer’s diseases: the therapeutic split? Eur Heart J. 2015;36(15):902–5.

    Article  PubMed  CAS  Google Scholar 

  26. Langenickel TH, Tsubouchi C, Ayalasomayajula S, Pal P, Valentin MA, Hinder M, et al. The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol. 2016;81(5):878–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Schoenfeld HA, West T, Verghese PB, Holubasch M, Shenoy N, Kagan D, et al. The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey. Toxicol Appl Pharmacol. 2017;323:53–65.

    Article  PubMed  CAS  Google Scholar 

  28. Cannon JA, Shen L, Jhund PS, Kristensen SL, Køber L, Chen F, et al. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail. 2017;19(1):129–37.

    Article  PubMed  CAS  Google Scholar 

  29. Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. 2016;9(1). https://doi.org/10.1161/CIRCHEARTFAILURE.115.002560.

  30. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333–40.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Senni M, McMurray JJ, Wachter R, McIntyre HF, Reyes A, Majercak I, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016;18(9):1193–202.

    Article  PubMed  CAS  Google Scholar 

  32. Vardeny O, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF study. American Heart Association Scientific Sessions, New Orleans, LA, USA; 2016.

  33. Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016;18(10):1228–34.

    Article  PubMed  CAS  Google Scholar 

  34. • Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K, et al. Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial. JACC Heart Fail. 2016;4(10):816–22. This secondary analysis of PARADIGM-HF found that 20% of patients who had never been hospitalized for heart failure prior to enrollment experienced the primary endpoint of cardiovascular death or heart failure hospitalization during the trial. The benefit of sacubitril-valsartan vs. enalapril was consistent regardless of recent clinical stability.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Division, Brigham & Women’s Hospital, 75 Francis St., Boston, MA, 02115, USA

    Joanna M. Joly MD & Akshay S. Desai MD

Authors
  1. Joanna M. Joly MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akshay S. Desai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akshay S. Desai MD.

Ethics declarations

Conflict of Interest

Joanna M. Joly declares no potential conflicts of interest.

Akshay S. Desai reports grant support and personal fees from Novartis. Dr. Desai reports personal fees from Abbott, AstraZeneca, Relypsa, and DalCor Pharma.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Heart Failure

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Joly, J.M., Desai, A.S. Sacubitril/Valsartan: From Clinical Trials to Real-world Experience. Curr Treat Options Cardio Med 20, 45 (2018). https://doi.org/10.1007/s11936-018-0638-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-018-0638-7

Keywords

Search

Navigation